Merck Announces Results From Phase 3 Studies of ZEPATIER™ (Elbasvir and Grazoprevir) in Chronic Hepatitis C Patient Populations at The International Liver Congress™

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from two Phase 3 clinical trials evaluating ZEPATIER™ (elbasvir and grazoprevir) 50mg/100mg tablets in chronic hepatitis C (HCV) patients with inherited blood disorders (C-EDGE IBLD) and in patients with a history of intravenous drug use who are receiving opioid agonist therapy (C-EDGE CO-STAR), respectively. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Sarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Hepatitis C Newsroom Corporate News Latest News #Merck #MRK $MRK International Liver Congress MSD ZEPATIER Source Type: news